Zobrazeno 1 - 10
of 140
pro vyhledávání: '"MARGARET MOLINE"'
Autor:
Maha Ahmad, James Kelly, C. Brendan Montano, Dinesh Kumar, Carlos Perdomo, Manoj Malhotra, Jess Amchin, Margaret Moline
Publikováno v:
Sleep Medicine: X, Vol 7, Iss , Pp 100098- (2024)
Objective: Few clinical studies have assessed real-world abrupt transitioning between insomnia medications. This study assessed strategies for directly transitioning patients from zolpidem tartrate (ZOL) immediate/extended release to the dual orexin
Externí odkaz:
https://doaj.org/article/990b45dcbbf74efabd62d2823908ac0d
Autor:
William R. Lenderking, Yulia Savva, Mark J. Atkinson, Renee Campbell, Isabelle Chabot, Margaret Moline, Genevieve Meier, Charles M. Morin
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 8, Iss 1, Pp 1-12 (2024)
Abstract Background The Insomnia Severity Index (ISI) is a widely used measure of insomnia severity. Various ISI research findings suggest different factor solutions and meaningful within-individual change (MWIC) to detect treatment response in patie
Externí odkaz:
https://doaj.org/article/7f9f97c9d0c94205b47b1870f1dab97e
Autor:
Valerie Arnold, Sonia Ancoli-Israel, Thien Thanh Dang-Vu, Kazuo Mishima, Kate Pinner, Manoj Malhotra, Margaret Moline
Publikováno v:
Neurology and Therapy, Vol 13, Iss 4, Pp 1081-1098 (2024)
Abstract Background Pharmacologic treatments are available to treat insomnia, a common and burdensome sleep disorder, but may be contraindicated in older adults who are prone to side effects from sleep-promoting drugs. These analyses of sleep diary d
Externí odkaz:
https://doaj.org/article/23ca3d2e802c4505a3c5dd1335916d83
Autor:
Yoshikazu Takaesu, Masahiro Suzuki, Margaret Moline, Kate Pinner, Kanako Inabe, Yurie Nishi, Kenichi Kuriyama
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 4, Pp 581-592 (2023)
Abstract Discontinuing long‐term pharmacotherapy for insomnia can result in rebound insomnia or withdrawal symptoms and suboptimal treatment. Post hoc analyses evaluated rebound insomnia and withdrawal symptoms among the subset of subjects from a p
Externí odkaz:
https://doaj.org/article/e3daed50698f49e49e0ccb649ef883aa
Autor:
Taro Kishi, Maika Nishida, Michinori Koebis, Takehiro Taninaga, Kenzo Muramoto, Naoki Kubota, Margaret Moline, Kenji Sakuma, Makoto Okuya, Ikuo Nomura, Nakao Iwata
Publikováno v:
Neuropsychopharmacology Reports, Vol 41, Iss 4, Pp 450-458 (2021)
Abstract Most conventional insomnia medications are gamma‐aminobutylic acid receptor agonists. However, physical dependence is a concern and one of the major limiting factors for long‐term treatment. The dual orexin receptor antagonists, suvorexa
Externí odkaz:
https://doaj.org/article/e1c3cd06cd9f45a8a585f4644d879cd0
Autor:
Amitabh Dash, Kate Pinner, Yuichi Inoue, Kenichi Hayashida, Sung Chul Lim, Chang-Ho Yun, Tsuo-Hung Lan, Chieh-Liang Huang, Jane Yardley, Naoki Kubota, Margaret Moline
Publikováno v:
Sleep Medicine: X, Vol 4, Iss , Pp 100044- (2022)
Study objectives: Lemborexant (LEM) is a dual orexin receptor antagonist approved for treating adults with insomnia. We analyzed the efficacy (subjective sleep outcomes) and safety of LEM over 12 months in the subgroup of Asian subjects from Study E2
Externí odkaz:
https://doaj.org/article/a8c72a7e621a4ab98e20c02d82cd3b54
Autor:
Satish Dayal, Jagadeesh Aluri, Nancy Hall, Gleb Filippov, Margaret Moline, Larisa Reyderman, Ishani Landry
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 2, Pp n/a-n/a (2021)
Abstract Lemborexant, a dual orexin receptor antagonist, is approved in the United States, Japan, and Canada for the treatment of insomnia in adults. This phase I, multicenter, open‐label, parallel‐group study assessed the impact of mild or moder
Externí odkaz:
https://doaj.org/article/b40a7b69298249d4a241b61fec67cc2a
Autor:
Ishani Landry, Jagadeesh Aluri, Nancy Hall, Gleb Filippov, Satish Dayal, Margaret Moline, Larisa Reyderman
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 2, Pp n/a-n/a (2021)
Abstract The primary aim of this study was to examine the effect of severe renal impairment (SRI) on the pharmacokinetics of lemborexant, a dual orexin receptor antagonist indicated for the treatment of insomnia. A phase 1 multicenter, single‐dose,
Externí odkaz:
https://doaj.org/article/e985b0e98d5745aa8710e3cb42b80741
Autor:
Ishani Landry, Jagadeesh Aluri, Nancy Hall, Dinesh Kumar, Satish Dayal, Margaret Moline, Larisa Reyderman
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 6, Pp n/a-n/a (2020)
Abstract Lemborexant is a dual orexin receptor antagonist approved for treating insomnia. As the solubility of lemborexant is pH‐sensitive, the impact of the gastric acid‐reducing agent (ARA), famotidine, on lemborexant pharmacokinetics was evalu
Externí odkaz:
https://doaj.org/article/1eed7e0a59224d89861190ba6336d821
Autor:
Marco DiBonaventura, Lance Richard, Maya Kumar, Anna Forsythe, Natalia M Flores, Margaret Moline
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0137117 (2015)
The aims of this study were (1) to compare health outcomes (i.e., health-related quality of life [HRQoL], productivity at work, and healthcare resource use visits) between those with insomnia and non-insomnia controls, (2) to compare health outcomes
Externí odkaz:
https://doaj.org/article/4d46d5c80e684eb094015ecac9a63435